K. Li

Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial

Shelagh B. Coutts, Sandeep Ankolekar, Ramana Appireddy et al. · The Lancet · 2024 · 101 citations · Full text

Thrombosis, Superiority Trial, Ischemic Stroke +12

Preoperative plasma D-dimer levels predict survival in patients with operable non-small cell lung cancer independently of venous thromboembolism

P.-P. Zhang, Junwei Sun, Xiao‐Yuan Wang et al. · European Journal of Surgical Oncology · 2013 · 70 citations

Thrombosis, Pulmonary Embolism, Surgical Oncology +8

OA13.03 Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double-Blind Phase 2 Trial

Ying Cheng, Q. Wang, K. Li et al. · Journal of Thoracic Oncology · 2018 · 58 citations · Full text

Clinical Therapeutic, Medicine, Metronomic Therapy +7

Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)

Ying Cheng, Q. Wang, K. Li et al. · Annals of Oncology · 2019 · 36 citations

Further-line Treatment, Oncology, Overall Survival +8

Prostasin: A Possible Candidate Gene for Human Hypertension

Haiyan Zhu, Dadong Guo, K. Li et al. · American Journal of Hypertension · 2008 · 24 citations · Full text